𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿

𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 is a foundation that empowers outstanding researchers and physicians to intercept the deadliest cancers.

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

We're speeding up cancer discoveries & reducing barriers with $50M in grants to @DanaFarber @HopkinsKimmel, @MSKCancerCenter, @kochinstitute, & @MDAndersonNews to find cures for some of the deadliest cancers. Learn more: https://t.co/QiSlMpO9cv #breakthroughcancer

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

We are tremendously grateful to the Venanzi family for their continued partnership, generosity, and commitment to advancing research with urgency and hope.

Read Emily's story: https://t.co/4uhBXhllAr

#CancerSurvivorMonth #ALKPositive #LungCancer #RadicalCollaboration

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

June is National #CancerSurvivorMonth & #ALKPositive Awareness Month.

When Emily Venanzi was diagnosed with metastatic ALK+ lung cancer in 2017, years of scientific discovery had already paved the way for targeted therapies that changed the course of her disease.

Today, Emily is helping drive the next generation of progress. As an advocate, scientist, and supporter of Break Through Cancer's PoweRD 2 Cure ALK+ Lung Cancer TeamLab, she and along with her husband, Patrick, are working to accelerate research for patients facing ALK+ lung cancer.

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

Read more about the TeamLab's findings: https://t.co/ijwe75YKfF

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

"𝙄𝙣𝙨𝙩𝙚𝙖𝙙 𝙤𝙛 𝙜𝙪𝙚𝙨𝙨𝙞𝙣𝙜 𝙬𝙝𝙚𝙩𝙝𝙚𝙧 𝙖 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙞𝙨 𝙬𝙤𝙧𝙠𝙞𝙣𝙜 𝙗𝙖𝙨𝙚𝙙 𝙤𝙣 𝙨𝙘𝙖𝙣𝙨 𝙖𝙡𝙤𝙣𝙚, 𝙬𝙚 𝙣𝙤𝙬 𝙝𝙖𝙫𝙚 𝙖 𝙢𝙤𝙡𝙚𝙘𝙪𝙡𝙖𝙧 𝙢𝙖𝙥 𝙩𝙝𝙖𝙩 𝙨𝙝𝙤𝙬𝙨 𝙝𝙤𝙬 𝙖𝙣𝙙 𝙬𝙝𝙚𝙧𝙚 𝙩𝙝𝙚 𝙞𝙢𝙢𝙪𝙣𝙚 𝙨𝙮𝙨𝙩𝙚𝙢 𝙞𝙨 𝙚𝙣𝙜𝙖𝙜𝙞𝙣𝙜 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝙩𝙪𝙢𝙤𝙧" - Dr Antonio Chiocca of @MassGenBrigham on the impact of the Accelerating GBM Therapies Through Serial Biopsies TeamLab.

On this #WorldBrainTumorDay are celebrating the researchers building that map and the patients who made that science possible. This TeamLab is working tirelessly to change the outlook for all patient with #GBM

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

Breakthroughs happen faster when researchers work together.
Proud to have the @TuftsUniversity veterinarian-scientists as part of the Defying Osteosarcoma TeamLab, uniting experts across institutions and disciplines to accelerate progress against this devastating disease.
#RadicalCollaboration #Osteosarcoma

[Tufts University @TuftsUniversity]

Tufts veterinarian-scientists join @break_cancer’s Defying Osteosarcoma TeamLab—the largest unified effort to study the disease—as part of a national effort to speed cures for osteosarcoma in people and pets.

https://t.co/hhtcjZIItW

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

The work is far from finished. As excitement builds, researchers are already focused on the next questions: how to achieve more durable responses and understand resistance to help further improve outcomes for patients—questions at the heart of our collaborative daraxonrasib study with Revolution Medicines, which is designed to understand not just whether this therapy works, but how and why it works in patients.

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

𝙏𝙝𝙞𝙨 𝙞𝙨 𝙩𝙝𝙚 𝙣𝙚𝙬𝙨 𝙬𝙚'𝙫𝙚 𝙗𝙚𝙚𝙣 𝙬𝙖𝙞𝙩𝙞𝙣𝙜 𝙛𝙤𝙧. 𝙏𝙝𝙞𝙨 𝙞𝙨 𝙩𝙝𝙚 𝙗𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝 — 𝙞𝙩'𝙨 𝙗𝙚𝙚𝙣 𝙖 𝙡𝙤𝙣𝙜 𝙩𝙞𝙢𝙚 𝙘𝙤𝙢𝙞𝙣𝙜.

That was how Tyler Jacks, PhD described the recent progress in KRAS-targeted therapies for pancreatic cancer to @Carolynyjohnson of the @washingtonpost.

This weekend at American Society of Clinical Oncology (ASCO), that momentum was on full display as Brian Wolpin presented @RevMedicines Phase 3 daraxonrasib results to a standing ovation.

https://t.co/f2HwzjaHhr

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

For decades, pancreatic cancer has remained one of the most difficult cancers to treat. These results represent an important milestone for patients and families, and for the scientists, clinicians, and trial participants who helped make them possible.

[Sandra Misale @Sandra_Misale]

Ieri ad #ASCO2026 ho visto una sala piena di oncologi, ricercatori e operatori sanitari alzarsi in piedi per applaudire uno studio clinico sul tumore del pancreas.
Per chi non lavora in oncologia può sembrare una cosa normale.
Per chi, come me, ha passato anni a studiare i tumori guidati da KRAS, è stato un momento che difficilmente dimenticherò.
🧵

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

@LeanneBMiller @DanaFarberNews @RevMedicines Hi @LeanneBMiller more than happy for you to use the video from Break Through Cancer

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

A powerful moment at #ASCO26
Dr Brian Wolpin (@DanaFarberNews) received a standing ovation during a field shifting plenary.
Overall survival data from @RevMedicines RASolute 302 trial - a true highlight from #ASCO2026
#PancreaticCancer

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

Minimal residual disease remains one of the biggest challenges in #OvarianCancer.

At #ASCO2026, Dr Helen Clark (@hdaifotisclark) from our Targeting MRD in Ovarian Cancer TeamLab presents work evaluating how ctDNA may enhance detection of high-risk minimal residual disease.

Advancing tools to identify residual disease and recurrence earlier is an important step toward more precise intervention and improved outcomes for patients.

[Anirban Maitra @Aiims1742]

The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al.
A seminal #ASCO26 plenary!
https://t.co/ub099PSsOq

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

Important moment for #PancreaticCancer at today's #ASCO2026 plenary

Dr. Brian Wolpin presents final analysis from the Phase 3 RASolute 302 study evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in previously treated metastatic PDAC.

These results mark meaningful progress for RAS-targeted therapy in pancreatic cancer and build on growing momentum across the field. We’re encouraged to see continued advances from @RevMedicines working to improve outcomes for patients.

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

Few targets have required more persistence than #KRAS.

At #ASCO2026, the @AACR / @ASCO joint session, The KRAS Journey—Perseverance Pays Off, brings together leaders from across the field to reflect on decades of discovery and the advances now reaching patients.

Looking forward to hearing from Dr. Eileen O'Reilly on what comes next for the field

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

. #ASCO2026 kicks off today.

It’s always exciting when the cancer research community comes together to share new science, challenge ideas, and learn from one another.

We look forward to following the advances emerging from this year’s meeting.

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

This week, members of the Accelerating #Glioblastoma Therapies Through Serial Biopsies TeamLab are gathering in person to dive into the data from their ongoing study.

Across two days, researchers will layout data from clinical outcomes and blood-based biomarkers to tumor evolution, immune response, spatial biology, and metabolomics. Data that will shape the next wave of publications to move these insights into the #CancerResearch community.

This is #RadicalCollaboration.

#BrainCancerAwarenessMonth

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

Taking the stage at 12.40 @bioitworld today:

“Radical Collaboration in Cancer Science: Building a Shared Platform for Cross-Institutional Discovery”

Break Through Cancer’s very own Michael Noble and Jon Grabenstatter will discuss how our radical collaboration model and investment in shared data science infrastructure is enabling cross-institutional discovery across the deadliest cancers.

#BioITWorld #BioITExpo #CancerResearch #DataScience #PrecisionMedicine

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

This #ClinicalTrialsDay, we are grateful to the patients and families who make progress in #CancerResearch possible.

Over the past five years, our clinical trials and research studies have reached hundreds of patients.

Together, these efforts are helping researchers better understand how cancers respond, evolve, and recur across #Glioblastoma, #AML, #PancreaticCancer, and #OvarianCancer.

Every patient who participates in research helps move the field forward and brings us closer to cures.

[Dana-Farber News @DanaFarberNews]

Watch @ABCNewsLive report on a pill showing promise in treating metastatic pancreatic cancer. @DanaFarber is leading research in this area, and @BHuffmanMD details his experience enrolling patients in these clinical trials.

➡️https://t.co/jryjjaMfl6